Table 2. Univariate and multivariate analysis of prognostic factors for OS.
| Prognostic Factor | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR(95%CI) | P | HR | p | |
| Tumor size (≤2 cm vs. >2 cm) | 1.85(1.441-2.366) | 0.04 | 1.51(1.166-1.961) | 0.02 |
| Tumor number (single vs. multiple) | 2.54(1.873-3.432) | <0.001 | 2.45(1.780-3.371) | <0.001 |
| CA19-9 (≤37 U/L vs. >37 U/L) | 2.18(1.627-2.912) | <0.001 | 1.61(1.181-2.210) | 0.03 |
| CEA (≤5 μg/L vs. >5 μg/L) | 2.29(1.687-3.110) | <0.001 | 1.64(1.186-2.264) | 0.03 |
| GGT (≤50 U vs. >50 U) | 2.11(1.581-2.828) | <0.001 | 1.42(1.043-1.949) | 0.04 |
| Adjunctive therapy (yes vs. no) | 0.85(0.637-1.129) | 0.26 | ||
| Vessel invasion (yes vs. no) | 1.17(0.782-1.747) | 0.72 | ||
| ALT (≤41 U vs. >41 U) | 1.29(0.906-1.817) | 0.16 | ||
| AST (≤38 U vs. >38 U) | 1.33(0.946-1.875) | 0.10 | ||
| TB (≤17.1 μmol/L vs. >17.1 μmol/L) | 0.94(0.522-1.679) | 0.83 | ||
| DB (≤7 μmol/L vs. >7 μmol/L) | 1.21(0.799-1.825) | 0.37 | ||
| Ascites (yes vs. no) | 1.37(0.606-3.081) | 0.45 | ||
| LND (yes vs. no) | 1.29(0.900-1.859) | 0.17 | ||
OS, overall survival; HR, Hazards ratio; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; GGT, gamma-glutamyl transferase; ALT, alanine aminotransferase; AST, aspartate transaminase; T, total bilirubin; DB, direct bilirubin; LND, lymph node dissection.